Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. announced its financial results for the fiscal year ended September 30, 2025, and provided a business update. The company reported a net loss of $24.8 million for FY2025, compared to $21.1 million in FY2024. Research and development expenses increased to $6.4 million from $4.9 million, and general and administrative expenses rose to $8.8 million from $8.1 million. Stock-based compensation also increased to $8.3 million from $7.5 million. The company ended FY2025 with $3.9 million in cash and cash equivalents. Significant events during the year included the U.S. commercial launch of LYMPHIR™ in December 2025 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). Citius Oncology also completed $36 million in strategic financings, including a $18 million offering in December 2025, to strengthen its cash position and support LYMPHIR's commercialization. The company has secured access to LYMPHIR in 19 international markets through Named Patient Programs and is collaborating with Verix to enhance commercial targeting using AI. Preliminary results from a Phase I trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors were also announced.